Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selumetinib increases the efficacy of first-line dacarbazine.

Cancer discovery - 1 Jul 2013

Abstract excerpt

Selumetinib plus dacarbazine prolongs progression-free survival in BRAF-mutant melanoma.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Benzimidazoles
Share to Dacarbazine
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Identifiers

PMID: 23847359
DOI: 10.1158/2159-8290.CD-RW2013-129

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Selumetinib increases the efficacy of first-line dacarbazine.PMID 23847359Read ↗

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.Semantic proximity Read ↗

In the pipeline: encorafenib and binimetinib in BRAF-mutated melanoma.Semantic proximity Read ↗

Development of encorafenib for BRAF-mutated advanced melanoma.Semantic proximity Read ↗

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.Semantic proximity Read ↗

Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy.Semantic proximity Read ↗

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.Semantic proximity Read ↗

Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.Semantic proximity Read ↗

An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.